Quick Answer
HALOZYME THERAPEUTICS, INC. reported Diluted EPS of $2.56 per share for fiscal year 2025.
HALOZYME THERAPEUTICS, INC. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | $2.56 | -25.4% |
| 2024 | $3.43 | +63.3% |
| 2023 | $2.10 | +45.8% |
| 2022 | $1.44 | -47.4% |
| 2021 | $2.74 | +201.1% |
| 2020 | $0.91 | +282.0% |
| 2019 | -$0.50 | +10.7% |
| 2018 | -$0.56 | -224.4% |
| 2017 | $0.45 | +155.6% |
| 2016 | -$0.81 | -224.0% |
| 2015 | -$0.25 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.43 | +36.2% | +7.5% |
| June 30, 2025 | $1.33 | +84.7% | +43.0% |
| March 31, 2025 | $0.93 | +55.0% | -11.4% |
| September 30, 2024 | $1.05 | +72.1% | +45.8% |
| June 30, 2024 | $0.72 | +28.6% | +20.0% |
| March 31, 2024 | $0.60 | +106.9% | -1.6% |
| September 30, 2023 | $0.61 | +38.6% | +8.9% |
| June 30, 2023 | $0.56 | +250.0% | +93.1% |
- HALOZYME THERAPEUTICS, INC. showed a decrease of -25.4% in Diluted EPS compared to the prior fiscal year.
- Over the 2015–2025 period, HALOZYME THERAPEUTICS, INC.’s diluted eps has grown by 1124.0% (from $0.25 per share (loss) to $2.56 per share).
- The most recent figure is from HALOZYME THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: